Loading...
MITO logo

Stealth BioTherapeutics CorpNasdaqGM:MITO Aktierapport

Marknadsvärde US$23.5m
Aktiekurs
n/a
Mitt verkliga värde
Ej tillgänglig
1Y-68.0%
7D-0.1%
1D
Portföljens värde
​
Utsikt

Stealth BioTherapeutics Corp

NasdaqGM:MITO Aktierapport

Börsvärde: US$23.5m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Stealth BioTherapeutics (MITO) Aktievy

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Mer information

MITO fundamental analys
Snöflinga Score
Värdering2/6
Framtida tillväxt0/6
Tidigare resultat0/6
Finansiell hälsa0/6
Utdelningar0/6

Belöningar

Intäkterna har ökat 14.4% per år under de senaste 5 åren

Riskanalys

Ger mindre än 1 miljon USD i intäkter ( $0 )

Negativt eget kapital

Har inte ett meningsfullt börsvärde ( $24M )

Aktieägarna har spätts ut under det senaste året

+ 2 fler risker

MITO Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Stealth BioTherapeutics Corp Konkurrenter

Prishistorik och prestanda

Sammanfattning av aktiekursernas upp- och nedgångar samt förändringar för Stealth BioTherapeutics
Historiska aktiekurser
Aktuell aktiekursUS$0.32
52 veckors högstaUS$1.03
52 veckors lägstaUS$0.16
Beta1.46
1 månads förändring1.75%
3 månaders förändring3.76%
1 års förändring-68.00%
3 års förändring-95.86%
5 års förändringn/a
Förändring sedan börsintroduktionen-97.31%

Senaste nyheter och uppdateringar

Seeking Alpha • Sep 30

Stealth Biotherapeutics chief financial officer Robert Weiskopf leaves company

Stealth BioTherapeutics (NASDAQ:MITO) said on Friday Robert Weiskopf, its chief financial officer, is leaving the company effective September 30. Weiskopf joined Stealth in 2019 following the initial public offering.
Seeking Alpha • Aug 01

Stealth BioTherapeutics shares pop ~20% premarket after co agrees to go private

Stealth BioTherapeutics (NASDAQ:MITO) on Monday said it had agreed to go private by being acquired by Morningside Venture (I) Investments, over a month after the clinical-stage biotech received the investment firm's preliminary proposal. MITO stock jumped 19.9% to $0.29 in premarket trading on the announcement. As per the terms of the deal, a consortium of investors led by Morningside for itself and on behalf of its affiliates and J. Wood Capital Advisors LLC will buy MITO for $0.03125 per share and $0.375 per ADS in an all-cash transaction. The per ADS consideration represents a 56.3% premium to Stealth's (MITO) last closing price of $0.24, and a 33.9% premium to the company's closing price of $0.28 on June 24, which was the last trading day before MITO said it had got the preliminary proposal. The Morningside led consortium intends to fund the merger through cash contributions from its members. MITO said its board had approved the deal and that the merger was expected to close during H2 this year.
Seeking Alpha • Jul 26

Stealth BioTherapeutics: A Net-Net Biopharma Going Private

This seems to be an interesting going private setup currently offering a 10% upside. Majority shareholder Morningside is acquiring the remaining 33% stake in a nanocap biopharmaceutical company Stealth BioTherapeutics. The buyer has indicated that it wants to complete the transaction swiftly and without broad due diligence. Offer cancellation risk seems to be low as the company is an advanced-stage biopharma that is currently trading below net cash while the buyer seems reputable and controls the company. On June 24, Morningside Venture Investments (MVIL) issued a non-binding proposal to acquire the remaining outstanding shares of a clinical-stage biopharmaceutical Stealth BioTherapeutics (MITO). MVIL already has a 67% stake in the company. The offer is $0.313 per ADS or $0.263 after deducting ADS cancellation fees. At current prices, this offers a 10% upside (after ADS fees). Majority-of-minority shareholder approval will not be needed while the committee of independent directors is likely to accept the deal given MVIL's influence over the company. I do not expect any regulatory scrutiny from CFIUS given MITO's size. In my view, the risks here boil down to whether MVIL can walk away from the acquisition. There are several reasons why offer withdrawal seems unlikely: MITO's key phase 3 drug for Barth Syndrome seems to have a good chance of being approved by the FDA despite its rejection in October 2021. The buyer seems to be a reputable Chinese PE/VC firm and already has full control over MITO. According to the acquisition proposal, MVIL is willing complete the transaction with a "superior degree of speed" and without broad due diligence which could point to a quick buyout timeline. MITO's stock price is currently below its most recently reported net cash levels ($0.27/ADS). However, the company is burning cash at a rapid pace - the latest estimate is that the company has enough cash to fund operating expenses into Q4'22. Having said that, offer withdrawal from the Chinese company remains a risk, particularly given non-binding nature of the proposal. In my experience, non-binding takeover offers from Chinese companies generally have a noticeably lower closing rate than binding proposals. Investors should also be aware that there is a possibility that the Chinese government interrupts the payment of funds to foreign shareholders if the merger closes. MITO MITO is a ~$16m market cap clinical-stage biopharma that was founded in 2006 and IPO'ed in 2019. The company is involved in mitochondrial medicine discovery, development and commercialization. The share price has continued to decline since going public and now MITO trades close to an all-time low. This can be attributed to a couple of the company's operational failures: In 2019, MITO failed a phase 3 drug trial for a primary mitochondrial myopathy ((PNM)) drug. This was a key reason behind the 75%+ share price plunge in Dec'19. In May 2022, the company failed a phase 2 trial for elamipretide treatment for blind people. In July 2022 (already after the non-binding offer announcement) - shares sold off 15% on 5x heavier volume upon receipt of NASDAQ non-compliance warning - unlikely to be an issue while the current transaction is pending. Since the 2019 failure, the company's most advanced drug has been elamipretide for treatment of Barth Syndrome. It's currently in its Phase 3 trial. MITO has sought FDA approval for the drug since 2021. However, last fall, the FDA declined to review MITO's NDA (new drug application) as it lacked additional controlled data. The FDA recommended designing a new clinical trial instead of using historical medical records of patients as control group data. Recently, however, the drug was granted a pre-NDA meeting. Reportedly, MITO will present new clinical data collected over 3.5 years, however, it will come from the same open-label extension of the ongoing phase 2/3 study and not a new trial. The FDA has previously said that an open-label extension study would not provide enough evidence to support an NDA. However, there are several reasons to expect the FDA to eventually approve the drug: The original application showed that trial goals were met - the problem was that the data was compared to historical medical records. Nevertheless, this is encouraging and likely shows the drug's efficacy. The company has also emphasized that the trial results have been "durable" across all patients. Barth Syndrome is an ultra-rare disease - only around 130 individuals in the US have the condition. For this reason, a new clinical trial is inherently hard to design and carry out. MITO has also stated that the FDA itself did not identify a suitable trial design. BridgeBio Pharma's first FDA approval for a rare disease in early 2021 appears to be a similar case. The clinical trial relied on the same design as MITO's - historical medical records were used as control data. MITO has openly said that it did not expect the first NDA to be approved but was rather pushed by a community of Barth Syndrome advocates. The fact that now MITO has new data is encouraging. The drug for Barth Syndrome has already received orphan drug, rare pediatric and fast track designations from the FDA, showing its uniqueness and essentiality for some part of the population. There are no FDA-approved drugs for the disease and other treatments are potentially years away. The meeting is expected in Q3'22. Overall, FDA approval is far from guaranteed but it is clearly a high-potential phase 3 drug and probably explains why the controlling shareholder wants to cash out minority shareholders before the expected approval.

Recent updates

Seeking Alpha • Sep 30

Stealth Biotherapeutics chief financial officer Robert Weiskopf leaves company

Stealth BioTherapeutics (NASDAQ:MITO) said on Friday Robert Weiskopf, its chief financial officer, is leaving the company effective September 30. Weiskopf joined Stealth in 2019 following the initial public offering.
Seeking Alpha • Aug 01

Stealth BioTherapeutics shares pop ~20% premarket after co agrees to go private

Stealth BioTherapeutics (NASDAQ:MITO) on Monday said it had agreed to go private by being acquired by Morningside Venture (I) Investments, over a month after the clinical-stage biotech received the investment firm's preliminary proposal. MITO stock jumped 19.9% to $0.29 in premarket trading on the announcement. As per the terms of the deal, a consortium of investors led by Morningside for itself and on behalf of its affiliates and J. Wood Capital Advisors LLC will buy MITO for $0.03125 per share and $0.375 per ADS in an all-cash transaction. The per ADS consideration represents a 56.3% premium to Stealth's (MITO) last closing price of $0.24, and a 33.9% premium to the company's closing price of $0.28 on June 24, which was the last trading day before MITO said it had got the preliminary proposal. The Morningside led consortium intends to fund the merger through cash contributions from its members. MITO said its board had approved the deal and that the merger was expected to close during H2 this year.
Seeking Alpha • Jul 26

Stealth BioTherapeutics: A Net-Net Biopharma Going Private

This seems to be an interesting going private setup currently offering a 10% upside. Majority shareholder Morningside is acquiring the remaining 33% stake in a nanocap biopharmaceutical company Stealth BioTherapeutics. The buyer has indicated that it wants to complete the transaction swiftly and without broad due diligence. Offer cancellation risk seems to be low as the company is an advanced-stage biopharma that is currently trading below net cash while the buyer seems reputable and controls the company. On June 24, Morningside Venture Investments (MVIL) issued a non-binding proposal to acquire the remaining outstanding shares of a clinical-stage biopharmaceutical Stealth BioTherapeutics (MITO). MVIL already has a 67% stake in the company. The offer is $0.313 per ADS or $0.263 after deducting ADS cancellation fees. At current prices, this offers a 10% upside (after ADS fees). Majority-of-minority shareholder approval will not be needed while the committee of independent directors is likely to accept the deal given MVIL's influence over the company. I do not expect any regulatory scrutiny from CFIUS given MITO's size. In my view, the risks here boil down to whether MVIL can walk away from the acquisition. There are several reasons why offer withdrawal seems unlikely: MITO's key phase 3 drug for Barth Syndrome seems to have a good chance of being approved by the FDA despite its rejection in October 2021. The buyer seems to be a reputable Chinese PE/VC firm and already has full control over MITO. According to the acquisition proposal, MVIL is willing complete the transaction with a "superior degree of speed" and without broad due diligence which could point to a quick buyout timeline. MITO's stock price is currently below its most recently reported net cash levels ($0.27/ADS). However, the company is burning cash at a rapid pace - the latest estimate is that the company has enough cash to fund operating expenses into Q4'22. Having said that, offer withdrawal from the Chinese company remains a risk, particularly given non-binding nature of the proposal. In my experience, non-binding takeover offers from Chinese companies generally have a noticeably lower closing rate than binding proposals. Investors should also be aware that there is a possibility that the Chinese government interrupts the payment of funds to foreign shareholders if the merger closes. MITO MITO is a ~$16m market cap clinical-stage biopharma that was founded in 2006 and IPO'ed in 2019. The company is involved in mitochondrial medicine discovery, development and commercialization. The share price has continued to decline since going public and now MITO trades close to an all-time low. This can be attributed to a couple of the company's operational failures: In 2019, MITO failed a phase 3 drug trial for a primary mitochondrial myopathy ((PNM)) drug. This was a key reason behind the 75%+ share price plunge in Dec'19. In May 2022, the company failed a phase 2 trial for elamipretide treatment for blind people. In July 2022 (already after the non-binding offer announcement) - shares sold off 15% on 5x heavier volume upon receipt of NASDAQ non-compliance warning - unlikely to be an issue while the current transaction is pending. Since the 2019 failure, the company's most advanced drug has been elamipretide for treatment of Barth Syndrome. It's currently in its Phase 3 trial. MITO has sought FDA approval for the drug since 2021. However, last fall, the FDA declined to review MITO's NDA (new drug application) as it lacked additional controlled data. The FDA recommended designing a new clinical trial instead of using historical medical records of patients as control group data. Recently, however, the drug was granted a pre-NDA meeting. Reportedly, MITO will present new clinical data collected over 3.5 years, however, it will come from the same open-label extension of the ongoing phase 2/3 study and not a new trial. The FDA has previously said that an open-label extension study would not provide enough evidence to support an NDA. However, there are several reasons to expect the FDA to eventually approve the drug: The original application showed that trial goals were met - the problem was that the data was compared to historical medical records. Nevertheless, this is encouraging and likely shows the drug's efficacy. The company has also emphasized that the trial results have been "durable" across all patients. Barth Syndrome is an ultra-rare disease - only around 130 individuals in the US have the condition. For this reason, a new clinical trial is inherently hard to design and carry out. MITO has also stated that the FDA itself did not identify a suitable trial design. BridgeBio Pharma's first FDA approval for a rare disease in early 2021 appears to be a similar case. The clinical trial relied on the same design as MITO's - historical medical records were used as control data. MITO has openly said that it did not expect the first NDA to be approved but was rather pushed by a community of Barth Syndrome advocates. The fact that now MITO has new data is encouraging. The drug for Barth Syndrome has already received orphan drug, rare pediatric and fast track designations from the FDA, showing its uniqueness and essentiality for some part of the population. There are no FDA-approved drugs for the disease and other treatments are potentially years away. The meeting is expected in Q3'22. Overall, FDA approval is far from guaranteed but it is clearly a high-potential phase 3 drug and probably explains why the controlling shareholder wants to cash out minority shareholders before the expected approval.
Seeking Alpha • Jul 11

Stealth BioTherapeutics receives Nasdaq non-compliance receipt

A clinical-stage biotechnology company, Stealth BioTherapeutics (NASDAQ:MITO) received a letter from Nasdaq on July 7, 2022 for not meeting with minimum bid price and market value of listed securities requirements.  Company requests an appeal, trading of the company's ADS will be suspended at the opening of business on July 18, 2022. Shares +1.1% after hours
Analysartikel • Dec 31

Reflecting on Stealth BioTherapeutics' (NASDAQ:MITO) Share Price Returns Over The Last Year

Stealth BioTherapeutics Corp ( NASDAQ:MITO ) shareholders should be happy to see the share price up 15% in the last...

Aktieägarnas avkastning

MITOUS BiotechsUS Marknad
7D-0.1%1.0%1.3%
1Y-68.0%34.2%27.7%

Avkastning vs industri: MITO presterade sämre än US Biotechs branschen som gav 34.2 % under det senaste året.

Avkastning vs Marknaden: MITO presterade sämre än US marknaden som gav 27.7 % under det senaste året.

Prisvolatilitet

Is MITO's price volatile compared to industry and market?
MITO volatility
MITO Average Weekly Movement1.5%
Biotechs Industry Average Movement10.9%
Market Average Movement7.2%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.0%

Stabil aktiekurs: MITO har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.

Volatilitet över tid: MITO s veckovolatilitet har minskat från 14% till 2% under det senaste året.

Om företaget

GrundadAnställdaVD OCH KONCERNCHEFWebbplats
200638Reenie McCarthywww.stealthbt.com

Stealth BioTherapeutics Corp Sammanfattning av grunderna

Hur förhåller sig Stealth BioTherapeutics:s resultat och omsättning till dess börsvärde?
MITO grundläggande statistik
BörsvärdeUS$23.54m
Vinst(TTM)-US$52.53m
Intäkter(TTM)n/a
0.0x
P/S-förhållande
-0.4x
P/E-förhållande

Är MITO övervärderat?

Se Verkligt värde och värderingsanalys

Resultat & intäkter

Viktig lönsamhetsstatistik från den senaste resultatrapporten (TTM)
MITO resultaträkning (TTM)
IntäkterUS$0
Kostnad för intäkterUS$0
BruttovinstUS$0
Övriga kostnaderUS$52.53m
Intäkter-US$52.53m

Senast redovisade vinst

Dec 31, 2021

Nästa vinstdatum

n/a

Vinst per aktie (EPS)-0.71
Bruttomarginal0.00%
Nettovinstmarginal0.00%
Skuld/egenkapitalförhållande-30.1%

Hur har MITO utvecklats på lång sikt?

Se historisk utveckling och jämförelse

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2022/11/16 09:43
Aktiekurs vid dagens slut2022/11/15 00:00
Intäkter2021/12/31
Årlig intjäning2021/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Stealth BioTherapeutics Corp bevakas av 9 analytiker. 2 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
null nullBMO Capital Markets Equity Research
Charles DuncanCantor Fitzgerald & Co.
Joshua SchimmerEvercore ISI